1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile

BACKGROUND: Clostridioides difficile infection (CDI) is recognised by the CDC as an “urgent threat” in the USA, responsible for nearly 13,000 deaths, and carries an economic burden ranging from &5.4 to &6.3 billion per year. In a phase II study, ridinilazole was shown to be effective at trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, Clive, Avis, Tim, Coward, Chris, Powell, David, Duperchy, Esther, Hu, Chenlin, Jahangir Alam, M, Begum, Khurshida, Garey, Kevin W, Reich, Stefanie, Moss, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644762/
http://dx.doi.org/10.1093/ofid/ofab466.1246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644762/
http://dx.doi.org/10.1093/ofid/ofab466.1246

Ejemplares similares